Development and characterization of a novel TDP‐43 positron emission tomography tracer: [ 18 F]JNJ‐TDP43‐1
Alzheimer's & Dementia · 2026-07 · 22 (7)
DOI: 10.1002/alz.71675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 18.07.2026. Verfasst von Chunfang A Xia und 10 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Technologies and Molecular Pharmacology, Johnson & Johnson, San Diego, California, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography, DNA-Binding Proteins, Brain, Radiopharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson, Johnson and Johnson.
Abstract (Originalsprache)
INTRODUCTION Neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), limbic‐predominant age‐related TDP‐43 encephalopathy (LATE), and Alzheimer's disease (AD) are associated with TAR DNA‐binding protein 43 (TDP‐43) pathology. A positron emission tomography (PET) tracer targeting TDP‐43 aggregates could improve early diagnosis and guide treatment development for TDP‐43–related conditions. METHODS Specific binding was evaluated using fluorescent labeling of compound, surface plasmon resonance (SPR), and autoradiography (ARG). Brain PET imaging in rats, nonhuman primate (NHP), and a disease mouse model was performed to characterize tracer pharmacokinetics and in vivo target binding. RESULTS JNJ‐TDP43‐1 exhibited high binding affinity for pathological TDP‐43 (K d = 7.1 nM) and remarkable selectivity over other proteinopathies. PET imaging demonstrated robust brain uptake and rapid washout in rodents and NHP. In vivo target engagement was confirmed in an AAV‐hTDP43 disease model. DISCUSSION [ 18 F]JNJ‐TDP43‐1 is a promising PET ligand for early diagnosis and evaluating therapies in TDP‐43‐related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery Technologies and Molecular Pharmacology, Johnson & Johnson, San Diego, California, USA.
- Neuroscience Biomarkers, Johnson & Johnson, San Diego, California, USA.
- Global Discovery Chemistry, Johnson & Johnson, San Diego, California, USA.
- Global Discovery Chemistry, Johnson & Johnson, Toledo, Spain.
- Preclinical Sciences and Translational Safety, Johnson & Johnson, San Diego, California, USA.
Förderung
- Johnson & Johnson
- Johnson and Johnson
Zitieren
APA
Xia, C. A., Salarian, M., Gartshore, C. J., Scaglione, A., Hayes, T., Liu, S., Tsai, H. M., Echavarren, J., Cid, J. M., Matzeu, A., & Szardenings, A. K. (2026). Development and characterization of a novel TDP‐43 positron emission tomography tracer: [ 18 F]JNJ‐TDP43‐1. Alzheimer's & Dementia, 22(7). https://doi.org/10.1002/alz.71675
Vancouver
Xia CA, Salarian M, Gartshore CJ, Scaglione A, Hayes T, Liu S, et al. Development and characterization of a novel TDP‐43 positron emission tomography tracer: [ 18 F]JNJ‐TDP43‐1. Alzheimer's & Dementia. 2026;22(7). doi:10.1002/alz.71675
BibTeX
@article{Xia2026,
author = {Xia, Chunfang A and Salarian, Mani and Gartshore, Christopher J and Scaglione, Antonella and Hayes, Thomas and Liu, Shuanglong and Tsai, Hsiu-Ming and Echavarren, Javier and Cid, Jose Maria and Matzeu, Alessandra and Szardenings, A Katrin},
title = {Development and characterization of a novel TDP‐43 positron emission tomography tracer: [ 18 F]JNJ‐TDP43‐1},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {7},
doi = {10.1002/alz.71675}
}
EUVIMED